Maternal PBMCs from PE cases and gestational-age matched (range between 26–37 weeks) controls were stained with a viability marker and antibodies for immune and stem cell subsets from Panel 1 (A) CD3-APC, CD14-AlexaFluor700, CD16-FITC, CD19-PE-CF594, CD34-PE-Cy7, and CD56-PE or Panel 2 (B) CD3-APC, CD4-FITC, CD8-PerCp-Cy5.5, CD25-AlexaFluor700, CD56-PE, and CD127-PE-Cy7. Cells were fixed and cell sorting performed on FACS Aria with isolation of stem and immune cells subsets by serial gating on the live (viability negative, not shown) lymphocyte/monocyte population by size and granularity (FSC-A and SSC-A) and the following markers to isolate B cells (CD3/CD14 negative, CD19+), Monocytes (CD3 negative, CD14+), NK cells (CD3/CD14/CD19 negative/CD56+), stem cells (CD3/CD19/CD14/CD56 negative, CD34+) (A) and T cells (CD56 negative, CD3+) and Treg cells (CD3+/CD4+/ CD25high/ CD127low) (B)